<DOC>
	<DOCNO>NCT01807377</DOCNO>
	<brief_summary>This study design assess safety , tolerability pharmacokinetics multiple oral 200-mg dos PF-05175157 administer twice daily 14 day healthy overweight obese subject .</brief_summary>
	<brief_title>Multiple Dose Safety Tolerability , Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion eligible enrollment study : Healthy male and/or female subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG clinical laboratory test ) . Women must non childbearing potential . Body Mass Index ( BMI ) 25 35 kg/m2 inclusive ; total body weight &gt; 50 kg ( 110 lb ) . An informed consent document sign date subject . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Evidence history chronic ongoing current pulmonary disease . History smoke past 5 year history smoke 10 pack year , history evidence habitual use ( non smoke ) tobacco nicotine containing product . Active ocular disease include infection , glaucoma , seasonal allergy , dry eye symptom retinal/optic nerve disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>